PepGen Inc. (NASDAQ:PEPG - Free Report) - Stock analysts at Wedbush boosted their FY2028 EPS estimates for PepGen in a research note issued on Monday, December 16th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($1.85) for the year, up from their previous forecast of ($2.08). Wedbush currently has a "Outperform" rating and a $12.00 target price on the stock. The consensus estimate for PepGen's current full-year earnings is ($2.84) per share.
A number of other brokerages have also weighed in on PEPG. HC Wainwright restated a "buy" rating and set a $26.00 price objective on shares of PepGen in a research report on Friday, November 8th. Bank of America cut PepGen from a "neutral" rating to an "underperform" rating and set a $3.00 price target for the company. in a report on Monday.
Check Out Our Latest Report on PEPG
PepGen Trading Up 0.7 %
PEPG traded up $0.03 during trading on Thursday, hitting $4.09. 59,624 shares of the company traded hands, compared to its average volume of 131,880. The company has a market cap of $133.32 million, a PE ratio of -1.37 and a beta of 1.56. PepGen has a 1 year low of $2.90 and a 1 year high of $19.30. The stock's 50-day simple moving average is $6.06 and its two-hundred day simple moving average is $10.42.
Institutional Investors Weigh In On PepGen
Several large investors have recently added to or reduced their stakes in PEPG. Janus Henderson Group PLC lifted its stake in shares of PepGen by 331.2% in the 3rd quarter. Janus Henderson Group PLC now owns 2,336,516 shares of the company's stock valued at $20,012,000 after purchasing an additional 1,794,641 shares during the last quarter. Suvretta Capital Management LLC lifted its position in PepGen by 9.2% in the third quarter. Suvretta Capital Management LLC now owns 1,660,932 shares of the company's stock worth $14,201,000 after buying an additional 140,000 shares during the last quarter. Sofinnova Investments Inc. increased its position in PepGen by 11.4% during the second quarter. Sofinnova Investments Inc. now owns 561,128 shares of the company's stock valued at $8,956,000 after acquiring an additional 57,504 shares during the last quarter. Walleye Capital LLC bought a new position in PepGen during the third quarter valued at $519,000. Finally, Bank of New York Mellon Corp lifted its holdings in shares of PepGen by 43.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 44,157 shares of the company's stock worth $705,000 after acquiring an additional 13,397 shares during the last quarter. 58.01% of the stock is owned by institutional investors.
PepGen Company Profile
(
Get Free Report)
PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.
Further Reading
Before you consider PepGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PepGen wasn't on the list.
While PepGen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
